Definiens Appoints Dr. Gerald Möller as Chairman of its Supervisory Board
Definiens AG, the leader in image analysis for Digital Pathology, today announced that Dr. Gerald Möller, has joined the company's supervisory board as an independent member and has been appointed chairman.
Munich, Germany, November 15, 2012 / B3C newswire / - Definiens AG, the leader in image analysis for Digital Pathology, today announced that Dr. Gerald Möller, has joined the company's supervisory board as an independent member and has been appointed chairman. Following the recent financing round, Dr. Möller will guide the expansion of Definiens' current business and the development and commercialization of innovative products for clinical Digital Pathology.
Definiens' image analysis solutions are currently deployed by all major biopharmaceutical companies, leading cancer centers and key pathology reference labs. Building on the leadership position in the life sciences sector, Definiens is rapidly growing its footprint in tissue based diagnostics, including the development of new companion diagnostic tests. These novel companion diagnostic tests will further accelerate the growth of Definiens' business in Clinical Digital Pathology.
"I am very excited to join Definiens' supervisory board at this defining point in time," commented Gerald Möller. "Quantitative Digital Pathology will not be possible without image analysis as provided by Definiens. I am very much looking forward to working with the Definiens team to further expand the leadership position in image analysis for Digital Pathology and grow the business in companion diagnostics and Clinical Digital Pathology."
Previously, Dr. Möller spent 23 years at Boehringer Mannheim in Germany, Japan and the US, where he held a number of leadership positions, including president of Decentralized Diagnostics, president of Advanced Diagnostics and Biochemicals, and CEO of Boehringer Mannheim Therapeutics. In 1995 he became CEO of the worldwide Boehringer Mannheim Group. Following the company's acquisition by Roche, Dr. Möller became head of Global Development and Strategic Marketing, Pharmaceuticals, and a member of the Executive Committee at Hoffmann LaRoche. In addition to Definiens, Dr. Möller is chairman of the board at Morphosys AG and sits on several further life sciences and diagnostics boards, including Illumina Inc., Bionostics Inc., and Vivacta Ltd. He also is chairman of the Foundation for Innovative New Diagnostics (FIND), a product development and implementation partnership financed in part by the Bill & Melinda Gates Foundation. He holds a Ph.D. in physical chemistry from the University of Kiel in Germany.
"We are delighted to have Dr. Möller as chairman of our board of directors. Gerald's strong track record in the healthcare space and his unmatched expertise in advanced diagnostics will be invaluable as Definiens expands into Clinical Digital Pathology," said Thomas Heydler, CEO of Definiens. "His commitment and vision will be instrumental to further strengthen Definiens as the leader in Quantitative Digital Pathology for life science research, tissue based companion diagnostics and clinical routine."
Related News
-
News Abortion pills can now be sold in retail pharmacies according to the US FDA
In the US, retail pharmacies will be allowed to sell abortion pills for the first time, after latest approval is granted by the FDA. -
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News CPHI Frankfurt: Interview with Marcelo Cruz, Vice President, Business Development & Marketing at Tjoapack
In this series of interviews, we caught up with some of the exhibitors at CPHI Frankfurt to discover what innovations are being brought to the pharmaceutical industry this year. Here we chat with Marcelo Cruz of Tjoapack to discuss how global events ar... -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News Trend Report: The True Cost of API Price Rises
Download our Trend Report to discover what the current landscape of APIs and their pricing means for the pharmaceutical industry in the future. -
News Alzheimer's drug lecanemab shows reduced cognitive decline in clinical trial
A monoclonal antibody drug, named lecanemab, has been tested in a Phase III clinical trial in nearly 1800 participants, with promising results in reducing the effects of Alzheimer's disease on the brain.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance